TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02738879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg, oral, once daily for 30 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin XR
Description: At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
Study: NCT00451893

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein operation with a heavy-weight mesh
Description: Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein operation with a light-weight mesh
Description: Johnson\&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
Study: NCT02078453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in the children related or not to the dental caries.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental treatment
Description: Dental treatment of all dental needs present in the children related or not to the dental caries.
Study: NCT04697420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
Study: NCT00399412

Intervention type: DEVICE
Intervention: subcutaneous ICD

Intervention type: DEVICE
Intervention: subcutaneous ICD

Intervention type: DEVICE
Intervention: subcutaneous ICD

Intervention type: DEVICE
Intervention: subcutaneous ICD
Study: NCT03527810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy Without Interrogation of Hiatus
Description: Weight-loss procedure to reduce the stomach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy With Interrogation of Hiatus
Description: Weight-loss procedure to reduce the stomach with hiatal repair.
Study: NCT01814293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handheld humidifier
Description: Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) \& control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
Study: NCT00751049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PhXA41
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Study: NCT03555565

Intervention type: DRUG
Intervention: Alogliptin and Metformin hydrochloride
Description: Alogliptin and Metformin hydrochloride combination tablets
Study: NCT04986410

Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA, CT-MPI, CT-FFR, SPECT-MPI
Description: Subjects undergo CCTA, CT-MPI, CT-FFR or SPECT-MPI
Study: NCT00759460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: 12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Study: NCT04870099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters in Times of Stress: An Illustrated Guide
Description: From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances.
Study: NCT02251145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Study: NCT00214149

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: breast brachytherapy to 34 Gy
Study: NCT04010903

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assessment of biomarkers of insulin resistance
Description: blood and urine sample collection for assays of BCAAs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assessment of biomarkers of insulin resistance
Description: blood and urine sample collection for assays of BCAAs

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: assessment of biomarkers of insulin resistance
Description: blood and urine sample collection for assays of BCAAs
Study: NCT04081090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain HQ Cognitive Modules
Description: Online personalized cognitive therapy modules to address and improve neuroplasticity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain HQ Cognitive Modules
Description: Online personalized cognitive therapy modules to address and improve neuroplasticity.
Study: NCT01504607

Intervention type: PROCEDURE
Intervention: Congenital Cataract Surgery
Description: Congenital cataract surgery with IOL implantation
Study: NCT02983149

Intervention type: DEVICE
Group type: OTHER
Intervention: Double lumen tube
Description: Use an double lumen tube to achieve one lung ventilation in thoracic surgeries

Intervention type: DEVICE
Group type: OTHER
Intervention: Fuji blocker
Description: Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries

Intervention type: DEVICE
Group type: OTHER
Intervention: EZ blocker
Description: Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
Study: NCT00438100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
Study: NCT01893060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluronic Cream
Description: Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
Study: NCT03104062

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microbubble Contrasted Echocardiography
Description: Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Microbubble Contrasted Echocardiography
Description: Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Platelet Aggregability
Description: Obtained using Multiplate Analyzer

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Platelet Aggregability
Description: Obtained using Multiplate Analyzer

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Laboratory
Description: it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Laboratory
Description: it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
Study: NCT00818467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tanning spray
Description: using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UVB
Description: receiving 40mJ UV-B phototherapy three times a week for four weeks
Study: NCT00154778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol, UFT,Leucovorin
Study: NCT04374162

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEEP
Description: different PEEP set on the anesthetic machine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP
Description: different PEEP set on the anesthetic machine
Study: NCT03144271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo will be administered subcutaneously (s.c. under the skin)
Study: NCT01751334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Description: Mobile Bearing Total knee Arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: Fixed Total Knee Arthroplasty
Study: NCT03909750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AD-cSVF
Description: Isolation of AD-cSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline IV
Description: Normal Saline IV containing AD-cSVF
Study: NCT00985998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab and chemotherapy
Description: The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4\~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4\~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12\~18 weeks).
Study: NCT01092039

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactoferrin, L-Glutamine and beta-glucans
Description: Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactoferrin, L-Glutamine and beta-glucans
Description: Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
Study: NCT02554058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling and Mechanical stimulation
Description: Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
Study: NCT04794374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
Study: NCT02089958

Intervention type: PROCEDURE
Intervention: Laparoscopic incisional hernia repair
Description: Standardized laparoscopic incisional hernia repair with mesh
Study: NCT02553499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1248
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-1248
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study: NCT04188431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Is usually commercialized as dexamethasone phosphate as solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: prepared in the same intravenous volume to mimic experimental arm
Study: NCT05565040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision in concealed penis
Description: comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision in concealed penis
Description: comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision in concealed penis
Description: comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics
Study: NCT04597541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
Study: NCT01819428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV120101 (Poziotinib)
Description: NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
Study: NCT01572493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15 (10 DAYS)
Description: Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15 (5 DAYS)
Description: Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15 (5 DAYS)
Description: Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-15 (5 DAYS)
Description: Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
Study: NCT02312362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined sclerotomy ab interno and phaco

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification with IOL implantation
Study: NCT03156608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novii ECG/EKG System
Description: External fetal heart rate monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External fetal heart rate monitoring
Description: External fetal heart rate monitoring
Study: NCT00076063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452)
Description: experimental vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452)
Description: experimental vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452)
Description: experimental vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1452)
Description: experimental vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIPO-5
Description: experimental vaccine
Study: NCT03819322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: 12 week, oral, fixed dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: 12 week, oral, fixed dose
Study: NCT00076063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIPO-5
Description: experimental vaccine
Study: NCT03845582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK-001 oral capsule
Description: Daily administration for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Daily administration for 24 months
Study: NCT03689543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER beta agonist
Description: We propose to evaluate the efficacy of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. The effects of estradiol primarily occur through activation of two receptor subtypes, often with opposing outcomes: estrogen receptor (ER) alpha, and ER beta. We focus on ER beta because the beta estrogen receptor is reported to mediate the effects of estradiol on the serotonergic system and mediate the antidepressant-like effects of estradiol in the forced-swim test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER beta agonist
Description: We propose to evaluate the efficacy of a selective estrogen receptor (ER) beta agonist (Lilly Compound LY500307) to prevent estradiol withdrawal-induced mood symptoms. The effects of estradiol primarily occur through activation of two receptor subtypes, often with opposing outcomes: estrogen receptor (ER) alpha, and ER beta. We focus on ER beta because the beta estrogen receptor is reported to mediate the effects of estradiol on the serotonergic system and mediate the antidepressant-like effects of estradiol in the forced-swim test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01863316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Study: NCT02879656

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-operative treatment
Description: conservative treatment with 5 weeks cast immobilization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-operative treatment
Description: conservative treatment with 5 weeks cast immobilization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: operative treatment
Description: surgery with volar locking plate with modified Henry's volar approach

Intervention type: PROCEDURE
Group type: OTHER
Intervention: operative treatment
Description: surgery with volar locking plate with modified Henry's volar approach
Study: NCT02184585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence A
Description: FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence A
Description: FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence B
Description: FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence B
Description: FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence C
Description: Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence C
Description: Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).